A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

NCT01762995 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: Dolutegravir 50 mg
DRUG: Calcium Carbonate 1200 mg
DRUG: Ferrous Fumarate 324 mg

Sponsor

ViiV Healthcare

Collaborators

[object Object]